Empowered control of drugs’ dosage in chronic diseases

Projektinformationen

INSULCLOCK

ID Finanzhilfevereinbarung: 739148

DOI 10.3030/739148

Abgeschlossenes Projekt

EK-Unterschriftsdatum 25 Oktober 2016

Startdatum 1 November 2016

Enddatum 31 Juli 2018

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 1 482 087,50

EU-Beitrag € 1 037 461,25

Koordiniert durch

INSULCLOUD
Spain

Ziel

INSULCLOCK addresses the opportunity of providing a new product Within the growing market for diabetes care, a very serious and painful disease with an expected global patient pool of 380 million by 2025.
More specifically, INSULCLOCK approaches the insulin pens market which totaled above 8 billion € in 2013, with a 9% CAGR for the next years.
More than 25% of diabetics depend on insulin injections daily, and it is estimated that 2/3 of insulin volume is injected via injection pens. If treatment fails, there is high risk of complications related to vascular and nerve affection and even death.
The goal of our project is to launch market uptake of INCULCLOCK, a solution to really help diabetics and their caregivers in self-managing their disease. Thanks to the unique integration of smart electronic devices and wearable technologies, we create new demand both from patients already using insulin pens and those not doing so because of reliability issues. Also, around their caregivers, not involved today in business, creating an uncontested market space.
In the current market there are smart insulin pen devices, although several reasons make INSULCLOCK unique:
1. It automatically records all critical information related to insulin in-taking for diabetes treatment, without interfering activities of daily living.
2. It stores data taking full advantage of possibilities offered by the Cloud and mobile technologies, assuring security, assistance and privacy.
3. It is universal and reusable.
During Phase 1, further business opportunities have been detected, with pharmaceutical and health insurance companies, and relevant leads have been open. Additionally, market barriers and dynamics are fully understood now, allowing us for the definition of the work plan proposed in this Phase 2 application, which will last 15 months with a total budget of 1.48M€. Finally, we created the team, alliances and resources for international high growth. Now is our moment.

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › health care services › eHealth
• natural sciences › computer and information sciences › internet › internet of things
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › clinical medicine › endocrinology › diabetes
• engineering and technology › other engineering and technologies › food technology › food safety

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Thema/Themen

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

INSULCLOUD

• Netto-EU-Beitrag: € 1 037 461,25
• Adresse: JULIO PALACIOS, 29 13 Esc.A ; 28029 MADRID ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Comunidad de Madrid › Comunidad de Madrid › Madrid
• Region: Comunidad de Madrid › Comunidad de Madrid › Madrid
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 1 482 087,50